Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Affiliations

• ¹ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
• ² Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
• ³ Department of Urology, Mayo Clinic, Rochester, MN, USA.
• ⁴ Department of Medicine, UC San Diego, La Jolla, CA, USA.
• ⁵ Pusan National University, Yangsan Hospital, Yangsan, South Korea.
• ⁶ Department of Urology, University of Pennsylvania, Philadelphia, PA, USA.
• ⁷ BCG Oncology, Phoenix, AZ, USA.
• ⁸ Department of Urology, UC Irvine, Irvine, CA, USA.
• ⁹ Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
• ¹⁰ Department of Urology, SUNY Medical Center, Upstate, Syracuse, NY, USA.
• ¹¹ Department of Urology, Northwestern University Medical Center, Chicago, IL, USA.
• ¹² Chesapeake Urology, Hanover, MD, USA.
• ¹³ Spokane Urology, Spokane, WA, USA.
• ¹⁴ Korea University, Anam Hospital, Seoul, South Korea.
• ¹⁵ Chonnam National University, Hwasun Hospital, Bundang, South Korea.
• ¹⁶ Department of Urology, UT MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁷ Billings Clinic, Billings, MT, USA.
• ¹⁸ CG Oncology, Irvine, CA, USA.
• ¹⁹ Department of Urology, Vanderbilt University, Nashville, TN, USA.
• ²⁰ Department of Urology, Rush University Medical Center, Chicago, IL, USA.